Management of Streptococcus pneumoniae-Associated HUS
Streptococcus pneumoniae-associated HUS (Sp-HUS) should be managed with aggressive supportive care including renal replacement therapy when indicated, avoidance of fresh frozen plasma, and consideration of eculizumab for severe cases with multivisceral involvement or failure to respond to supportive measures.
Immediate Recognition and Diagnosis
Sp-HUS presents with the classic triad of microangiopathic hemolytic anemia (negative Coombs test), thrombocytopenia, and acute kidney injury in the setting of invasive pneumococcal disease 1. The primary infection is most commonly pneumonia (often complicated) or meningitis, with meningitis cases showing more severe clinical courses and higher mortality 2, 3.
Key diagnostic features include:
- Severe thrombocytopenia with schistocytes on peripheral blood smear
- Evidence of T-antigen activation (definite, probable, or possible cases based on serological testing) 1
- Isolation of Streptococcus pneumoniae from normally sterile sites
- Rapid progression requiring intensive care and ventilatory support 2
Critical Management Principles
Avoid Fresh Frozen Plasma
The most important pitfall to avoid is administration of fresh frozen plasma (FFP), which can worsen outcomes 3. The pathophysiology involves pneumococcal neuraminidase exposing the Thomsen-Friedenreich (T) antigen on red blood cells and endothelial cells. FFP contains anti-T antibodies that can bind these exposed antigens, exacerbating hemolysis and endothelial injury 1, 3.
Supportive Care Foundation
Provide aggressive supportive management:
- Renal replacement therapy when indicated (all patients in reported series required dialysis) 2, 4
- Blood transfusion for severe anemia (washed red blood cells preferred to avoid anti-T antibodies)
- Intensive care monitoring with ventilatory support as needed
- Appropriate antimicrobial therapy for the underlying pneumococcal infection 2
Eculizumab Consideration
Eculizumab (C5 complement inhibitor) should be considered for patients with severe multivisceral involvement or those failing to respond to supportive care 1, 5. Recent evidence demonstrates:
- Complement activation, particularly the alternative pathway, contributes to Sp-HUS pathophysiology beyond T-antigen exposure alone 6, 4
- Case reports show favorable outcomes with eculizumab in severe cases, including adult patients with multivisceral failure 5
- Genetic complement analysis in pediatric cases revealed alternative pathway activation and risk haplotypes 4
Important caveat: Randomized clinical trials are lacking, so eculizumab use remains based on case series and pathophysiologic rationale 1, 6. However, given the high mortality and morbidity of severe Sp-HUS, early consideration is warranted when supportive care proves insufficient.
Vaccination Considerations
Meningococcal vaccination is mandatory if eculizumab is initiated, with quadrivalent conjugate vaccine (A, C, W, Y) and serogroup B vaccine, plus antimicrobial prophylaxis with penicillin or macrolides for the duration of treatment 7.
Clinical Course and Prognosis
Expect prolonged hospitalizations (average 36 days, up to 99 days in complicated cases) 2. Approximately 70% of patients show progressive recovery of renal function, though some require ongoing dialysis 2, 4. Thrombotic vascular complications can occur, potentially requiring amputation 2. Long-term follow-up is essential as renal sequelae are common 1, 4.
Key Algorithmic Approach
- Recognize invasive pneumococcal disease with HUS triad
- Avoid FFP administration
- Initiate supportive care with dialysis as needed
- Consider eculizumab if severe multivisceral involvement or inadequate response within 48-72 hours
- Monitor for thrombotic complications and long-term renal sequelae